Abstract: The present technology provides a technology capable of performing stable liquid feeding. For this, the present technology provides a cell sample liquid feeding bag or the like including at least: an outflow port from which cell sample liquid flows out; a bottom portion including a reservoir unit capable of reserving cells and at least partly including a slope; and a first inner tube extending from the outflow port toward the reservoir unit to a position not contacting the reservoir unit, and the cell sample liquid is fed from a reservoir unit side toward an outflow port side of the first inner tube.

Abstract: A multi-chamber single-use bioreactor for cell culture expansion has bag assembly and a rigid support structure defining a bag receiving space. The bag assembly disposed in the bag receiving space of the rigid support structure and supported by the rigid support structure. The bag assembly has at least a first flexible bag and a second flexible bag. The first bag defines a first reaction chamber, and the second bag defines a second reaction chamber. The first reaction chamber has a first volume, a first inlet, and a first outlet, and the second reaction chamber has a second volume different from the first volume, a second inlet, and a second outlet. The second inlet of the second bag is fluidically connected to the first outlet of the first bag so liquid in first reaction chamber can be transferred to the second reaction chamber.

Abstract: The present invention provides a fluidic chip for cell culture use which can prevent a decrease in the activity of cultured cells in a preparation stage, and which makes it possible to observe a cultured cell tissue while detaching the cultured cell tissue from the fluidic chip.

Abstract: Provided herein are methods for culturing patient-derived tumor cell spheroids in a three-dimensional microfluidic device. The method comprises mincing primary tumor sample in a medium supplemented with serum; treating the minced primary tumor sample with a composition comprising an enzyme; collecting tumor spheroids having a diameter of 10 ?m to 500 ?m from the enzyme treated sample; suspending the tumor spheroids in biocompatible gel; and culturing the tumor spheroids in a three dimensional microfluidic device. Methods for identifying an agent for treating cancer and microfluidic devices that allow for the simultaneous exposure of the cultured patient-derived primary tumor cell spheroids to a treatment of choice and to control treatment are also provided.

Abstract: A culture membrane having a first surface is provided. The first surface has a plurality of protrusions. The tops of the protrusions and the gaps between the tops jointly form a culture portion adapted to culture cells. The culture portion has a hardness of 2 kPa to 500 kPa. The invention further provides a culture dish. The culture membrane of the invention and the culture dish using the same may increase the survival rate of cells.

Abstract: A method for washing particles includes obtaining an array plate that includes an array of hydrophilic areas surrounded by one or more hydrophobic areas. A respective solution containing a sample is located on a respective hydrophilic area of the array of hydrophilic areas. The respective hydrophilic area includes one or more indentations from a respective surrounding hydrophobic area of the one or more hydrophobic areas. The respective hydrophilic area includes a first indented surface that is offset from a reference surface defined by the respective surrounding hydrophobic area. The method also includes placing an aspirator nozzle above the respective hydrophilic area at a predefined distance from the first indented surface, and aspirating the solution with the aspirator nozzle while the aspirator nozzle is located at the predefined distance from the first indented surface.

Abstract: Described herein are systems and methods of flow-through electroporation can comprise a chamber with a first and a second portion, wherein the first portion is configured to receive cells and the second portion is in fluid communication with the first portion and is configured to receive cells from the first portion; an electrode can be present in the first portion, second portion, or both; a porous membrane can separate the first and second portions, the porous membrane can have one or more pores, and the pores can have one or more interior surfaces configured to allow cells from the first portion to pass through to the second portion; an electric generating device in electrical communication with one or more electrodes, the membrane, or the one or more electrodes and the membrane, wherein the electric generating device is configured to deliver constant voltage or one or more electric pulses to the system.

Abstract: The shock tube comprises a tube, a first electrode, a second electrode and a stopple, wherein the tube is internally provided with a cavity for accommodating a target liquid sample. The first electrode is arranged at one end of the tube. The second electrode is arranged in the stopple, and the outer end of the second electrode can be electrically connected with the exterior via an opening of the stopple. The stopple is internally provided with an elastic piece connected with the second electrode. The outer side of the elastic piece is connected with the stopple, and the inner side of the elastic piece is connected with the second electrode. The invention further provides a cell electroporation device where the shock tube can be placed.

Abstract: Provided are a culture device and a cell culture method using the culture device. The culture device includes: a temperature sensitive layer and a luminescence emitting structure. The luminescence emitting structure is connected to and overlaps with the temperature sensitive layer, and is configured to emit a cold light that travels through the temperature sensitive layer.

Abstract: Incubators including an enclosure with an internal chamber configured to support a cell culture plate comprising a plurality of wells are disclosed. The enclosure includes a plurality of openings configured to allow access to the wells. The incubators include a sealing element configured to seal the plurality of openings in the enclosure. The sealing element comprises a plurality of openings corresponding to at least a subset of the plurality of openings in the enclosure. Access to the internal chamber can be provided by aligning the plurality of openings in the sealing element with the plurality of openings in the enclosure. Methods for using the incubators are also provided.

Abstract: A method of measuring simply and accurately a microbial count in a sample. Namely, a method of measuring a microbial count including a step of blending a composition for preparing a culture medium for a microbial count measurement including (a) a polymer able to form a non-flowable transparent gel without a melting step by heating and without cooling, and (b) a nutrient component, with a sample added thereto, a step of incubating microorganisms contained in the sample, and a step of measuring the colony count of the microorganisms.

Abstract: A fluid supply interface includes at least one supply coupling configuration, at least one discharge coupling configuration, at least one user coupling configuration, and a fluid conduit that connects the supply, discharge, and user coupling configurations to one another. A supply valve is capable of having fluid flow through it or is blocked for flow through it. A discharge valve is capable of having fluid flow through it or is blocked for flow through it. The supply valve is preloaded into a blocking position that prevents flow, and opens by means of a sufficiently large pressure difference between the two sides of the supply valve, against the preload force, for flow through in a direction from the supply coupling configuration toward the fluid conduit. The discharge valve likewise being preloaded into a closed position that prevents flow through it.

Abstract: A cell detection device and a cell detection method is provided with which it is possible to efficiently acquire images of cells to be measured. Cell detection device comprises flow cell through which a measurement specimen that contains particles is caused to flow, particle detector for detecting the particles in the measurement specimen supplied to flow cell, particle sorter for sorting particles that satisfy a detection condition and other particles on the basis of the result of detection performed by particle detector, specimen supply part for supplying, to flow cell, an image-capture specimen that includes detection-condition-satisfying particles that have been sorted by particle sorter, and particle-image-capture part for capturing images of the particles in the sorted image-capture specimen supplied to flow cell.

Abstract: The present invention concerns a single use aseptic kit comprising: a disaggregation module for receipt and processing of material comprising solid mammalian tissue; and a stabilisation module for storing disaggregated product material, wherein each of the modules comprises one or more flexible containers connected by one or more conduits adapted to enable flow of the tissue material there between; and wherein each of the modules comprises one or more ports to permit aseptic input of media and/or reagents into the one or more flexible containers. The invention further relates to an automated device for semi-automated aseptic disaggregation and/or enrichment and/or stabilisation of cells or cell aggregates from mammalian solid tissue comprising a programmable processor and the single use aseptic kit. The invention further relates to a semi-automatic aseptic tissue processing method.

Abstract: The present invention provides a cell treatment apparatus capable of treating cells in a cell culture vessel. The cell treatment apparatus 100 according to the present invention includes a first region 1, a second region 3, and a third region 5. The first region 1 and the second region 3 are placed in succession. The first region 1 is a cell treatment chamber for treating cells. The cell treatment chamber can be closed from the outside of the cell treatment chamber and includes a culture vessel placement portion for placing a cell culture vessel. The second region 3 includes: a laser irradiation device capable of irradiating the cell culture vessel placed in the culture vessel placement portion with a laser; and a spot diameter adjustment device that adjusts a spot diameter formed in a portion to be irradiated with the laser in an object to be irradiated.

Abstract: The invention relates to a device for separating mobile cells, formed by two reservoirs that share a side formed by a perforated plate in which at least one channel has a narrowed diameter, adopting a conical shape. A sample containing the cells is deposited in the first reservoir and the second reservoir is filled with a culture medium, with a level mark higher than that of the first reservoir, producing a current towards same. The device is used to select, in a semen sample, the most suitable spermatozoa for use in assisted reproduction techniques.

Abstract: The invention belongs to the field of chemical analysis and detection, and specifically relates to a pretreatment method for LC-MS detecting metabolomics of Aspergillus flavus. The method includes: culturing a strain of Aspergillus flavus; quenching the Aspergillus flavus; disrupting the cell membrane of Aspergillus flavus, and extracting a metabolome. The invention adopts a cold glycerol buffer solution combined with a rapid filtration method for quenching, and a MeOH/DCM/ACN/EA/HCOOH mixture is used as an metabolome extract, thereby achieving the object of efficiently extracting different polar compounds, and metabolome compound coverage is high; pretreatment of the cell metabolomics of Aspergillus flavus by the method of the invention can ensure the repeatability and stability of the metabolomics analysis method and reduce the false positive of the test results.

Abstract: Presented herein are compositions and methods for the long-term in vitro culturing of Treponema species such as T. pallidum. Culture media and systems for Treponema culture are also provided.

Abstract: The invention is directed to a cell culture medium composition wherein the composition comprises an effective amount of: valproic acid; a GSK-3 inhibitor; a TGFPRI inhibitor; Forskolin; a JNK inhibitor; a protein kinase C (PKC) inhibitor; a Rho-associated, coiled-coil containing protein kinase (ROCK) inhibitor; at least one omega-3 fatty acid; a nutrient source, and any combination thereof.

Abstract: The present invention relates to photoreceptor precursor cells comprising a heterologous nucleic acid encoding an optogenetic inhibitor. The present invention also relates to a pharmaceutical composition comprising photoreceptor precursor cells of the invention and a pharmaceutically acceptable excipient. The present invention relates to photoreceptor precursor cells or pharmaceutical composition of the invention for use in the treatment of a retinal degenerative disease, preferably a retinal degenerative disease related to a loss of function or death of photoreceptors. Finally, the present invention relates to a method for producing the photoreceptor precursor cells of the invention, comprising i) providing photoreceptor precursor cells; and ii) introducing into said precursor cells a nucleic acid encoding optogenetic inhibitor.

Abstract: A method of generating photoreceptor cells is disclosed. Cell populations comprising photoreceptor cells and uses thereof are also disclosed.

Abstract: An object of the present invention is to provide a cell population comprising adherent cells having low differentiation capacity derived from a fetal appendage, methods for producing or using the same, and a pharmaceutical composition comprising the cell population, in particular wherein the proportion of CD73- and CD90-positive adherent cells derived from a fetal appendage is 90% or more; and the cell population satisfies a relative expression level of LFA-3 gene to the expression level of SDHA gene of 1.0 or more, in particular wherein the relative expression level of HAPLN1 gene to the expression level of SDHA gene is 4.0 or more and/or the relative expression level of CCND2 gene to the expression level of SDHA gene is 1.5 or less, in particular wherein the proportion of the STRO-1-negative adherent cells derived from a fetal appendage is 95% or more.

Abstract: The present disclosure relates to a method of generating bioartificial reptile leather by in vitro culturing of isolated cells the chorioallantois of hatched reptile eggs. The disclosure allows production of reptile leather without the ethical issues of conventional reptile farming and the trapping and killing of reptiles for their skin. Furthermore the disclosure allows production of reptile leather from species that are not abundantly available as skin products, such as from endangered species.

Abstract: The present invention relates to a method of generating ?? T cells having at least one down-regulated co-inhibitory receptor, the method comprising the steps of: (a) culturing a population of cells comprising ?? T cells with a phosphoantigen to expand the ?? T cells; and (b) culturing the expanded ?? T cells with artificial antigen-presenting cells expressing a Fc receptor, and an anti-CD3 antibody. The present invention also relates to ?? T cells generated according to a method of the present invention, as well as methods of treatment and medical uses thereof.

Abstract: This invention relates to the production of isolated naive regulatory T cells by detecting the presence or absence of a panel of surface markers comprising CD3, CD4, CD25, CD45RA, CCR4 and CCR7 on the surface of cells in a population of peripheral blood mononuclear cells (PBMCs); and separating cells on which the presence of the surface markers CD3, CD4, CD25, CD45RA, and CCR7 and the absence of the surface marker CCR4 is detected. Isolated populations of naive regulatory T cells and methods and kits for their production are provided.

Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.

Abstract: This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of NK cells by increasing the expression of specific transcription factors associated with NK cell production.

Abstract: Provided are methods of making innate immune cell compositions containing gamma.delta (??) T cells and/or Natural Killer (NK) cells, and the resulting compositions and related products of manufacture and kits for use in cancer and infectious disease therapy. The methods provided herein permit tailoring of the relative amounts of gamma.delta (??) T cells and Natural Killer (NK) cells in the compositions, for cellular therapies against a wide variety of cancers and infectious diseases. The resulting compositions can further be used to generate compositions containing either NK cells alone or gamma.delta T cells alone, for immune cellular therapies. The compositions provided herein also can be genetically altered: the gamma delta T cells and Natural Killer cells are modified to express chimeric antigen receptors (CARS) or exogenous T cell receptors (TCRs), which can be used to target any cell surface molecule either directly or indirectly, e.g., a marker on a cancer cell or an infected cell.

Abstract: The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of inflammatory rheumatic diseases.

Abstract: The present disclosure relates to genetically modified conditionally immortalized cells and cell lines, provided with a vector comprising a promoter sequence, at least one immortalization gene operably linked to the promoter sequence, a gene coding for an inducible regulator operably linked to the promoter sequence and a response element for the inducible regulator. The present disclosure further relates to methods for their preparation, and to immortalization and differentiation of such cells.

Abstract: An object of the present invention is to provide a novel myocardial stem cell for transplantation which enables maintenance of a therapeutic effect on and/or preventive effect against cardiac failure for a prolonged period, a method for producing the myocardial stem cell, and a cell preparation containing the myocardial stem cell. [Solution] The present invention relates to a method for producing a myocardial stem cell to be used for treatment and/or prevention of cardiac failure, the method comprising the step of introducing a complex of a mitochondria-targeting carrier and a mitochondria activating agent into a myocardial stem cell; a cell produced by the method and a cell preparation containing the cell; and a liposome to be used for producing the cell. According to the present invention, there can be provided a myocardial stem cell which is capable of maintaining a therapeutic effect and/or preventive effect by cell transplantation for a prolonged period.

Abstract: The fallopian tube epithelium (FTE) has been recognized as a site of origin of high-grade serous ovarian cancer (HGSC). However, absence of relevant in vitro human models that can recapitulate tissue-specific architecture has hindered understanding of FTE transformation and initiation of HGSC. Here, induced pluripotent stem cells (iPSCs) were used to establish a novel 3-dimensional (3D) human FTE organoid in vitro model containing the relevant cell types of the human fallopian tube as well as a luminal architecture that closely reflects the organization of fallopian tissues in vivo. Modulation of Wnt and nodal/activin signaling pathways provided iPSC differentiation into Müllerian cells and subsequent use of pro-Müllerian growth factors promoted FTE precursors. The expression of Müllerian markers verified correct cellular differentiation. An innovative 3D growth platform, which enabled the FTE organoid to self-organize into a convoluted luminal structure, permitted final differentiation to a FTE lineage.

Abstract: A cell cultivation method includes cultivating dedifferentiated kidney cells in a state of being non-adherent to a culture vessel for a period of 5 days or longer, forming aggregates of the kidney cells during the cultivation period, then cultivating the kidney cells in a state of having formed aggregates, during a portion of the period, and thereby restoring the physiological functions of the kidney cells.

Abstract: The present invention provides various improved systems and methods for obtaining, generating, culturing, and handling cells, such as stem cells (including induced pluripotent stem cells or iPSCs) and differentiated cells, as well as cells and cell panels produced using such systems and methods, and uses of such cells and cell panels.

Abstract: The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains.

Abstract: The present invention provides a herpes virus with improved oncolytic properties which comprises a gene encoding an immunomodulatory cytokine and which lacks a functional ICP34.5 gene and a functional ICP47 encoding gene.

Abstract: Modified AAV vectors and uses thereof are provided.

Abstract: The invention relates to methods of culturing cells, generating cell lines, and delivering polynucleotides to cells involving the use of HDAC inhibitors and/or adeno-associated virus (AAV) rep proteins.

Abstract: Provided is a host cell for stably propagating a virulent hand, foot and mouth disease virus, the host cell expressing no heparan sulfate and overexpressing primate scavenger receptor class B member 2 (SCARB2). Also provided is a method for screening for an anti-hand, foot and mouth disease virus vaccine or an anti-hand, foot and mouth disease virus drug using a stably cultured virulent hand, foot and mouth disease virus.

Abstract: The invention relates to a method for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.

Abstract: The present invention relates to a recombinant microbial host for the production of xylitol, the recombinant microbial host containing a nucleic acid sequence encoding a NAD+-specific D-arabitol 4-oxidoreductase (EC 1.1.1.11) using D-arabitol as substrate and producing D-xylulose as product, and a nucleic acid sequence encoding a NADPH-specific xylitol dehydrogenase using D-xylulose as substrate and producing xylitol as product.

Abstract: The present invention relates a polypeptide having kaurenoic acid 13-hydroxylase activity, which polypeptide comprises an amino acid sequence which, when aligned with a kaurenoic acid 13-hydroxylase comprising the sequence set out in SEQ ID NO: 1 or SEQ ID NO: 3, comprises at least one substitution of an amino acid corresponding to any of amino acids at positions 136, 248, 336 or 403, said positions being defined with reference to SEQ ID NO: 1 or SEQ ID NO: 3 and wherein the polypeptide has one or more modified properties as compared with a reference polypeptide having kaurenoic acid 13-hydroxylase activity. A polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.

Abstract: The disclosure relates to an oligosaccharyltransferase polypeptides and their use in the synthesis of glycoconjugates in bacterial cells; vaccines and immunogenic compositions comprising said glycoconjugates and their use in the prevention and/or treatment of bacterial infection. Bacterial expression system comprising said oligosaccharyltransferase polypeptides are also disclosed.

Abstract: The present invention provides engineered glycosyltransferase (GT) enzymes, polypeptides having GT activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention provides engineered sucrose synthase (SuS) enzymes, polypeptides having SuS activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention also provides compositions comprising the GT enzymes and methods of using the engineered GT enzymes to make products with ?-glucose linkages. The present invention further provides compositions and methods for the production of rebaudiosides (e.g., rebaudioside M, rebaudioside A, rebaudioside I, and rebaudioside D). The present invention also provides compositions comprising the SuS enzymes and methods of using them. Methods for producing GT and SuS enzymes are also provided.

Abstract: Provided are a variant of a haloacid dehalogenase superfamily protein, a polynucleotide encoding the variant, a recombinant microorganism including the variant, and a method of reducing a concentration of a fluorine-containing compound in a sample using the variant.

Abstract: Disclosed are methods and compositions for reduced immunogenic proteins used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are genetically engineered variants of N-acetylgalactosamine-6-sulfatase (GALNS), which are less immunogenetic then wild-type GALNS, but maintain enzymatic activity, and may be used to treat Mucopolysaccharidosis IVA (Morquio A disease, MPS IVA).

Abstract: The present disclosure generally relates to compositions and methods for improving the efficiency of homologous recombination. In particular, the disclosure relates to reagents and the use of such reagents.

Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and polynucleotides encoding the polypeptides, catalytic domains, cellulose binding domains and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.

Abstract: The present invention relates to polypeptides having mannanase activity, catalytic domains, and carbohydrate binding modules, and polynucleotides encoding the polypeptides, catalytic domains, and carbohydrate binding modules. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains, and carbohydrate binding modules.

Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.